Psychemedics (PMD) Stock Forecast, Price & News

Psychemedics' stock was trading at $4.9047 on January 1st, 2023. Since then, PMD shares have decreased by 1.9% and is now trading at $4.81.
View the best growth stocks for 2023 here.

Psychemedics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,700 shares, an increase of 24.5% from the April 30th total of 9,400 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is presently 1.7 days. Approximately 0.3% of the company's stock are sold short.
View Psychemedics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our PMD earnings forecast.

Psychemedics Co. (NASDAQ:PMD) released its earnings results on Tuesday, March, 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. The company earned $5.70 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 13.52% and a negative net margin of 6.13%.

Psychemedics announced a quarterly dividend on Tuesday, May 9th. Shareholders of record on Thursday, May 25th will be given a dividend of $0.07 per share on Thursday, June 8th. This represents a $0.28 annualized dividend and a yield of 5.82%. The ex-dividend date is Wednesday, May 24th.
Read our dividend analysis for PMD.

Psychemedics (NASDAQ:PMD) pays an annual dividend of $0.28 per share and currently has a dividend yield of 5.97%. PMD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PMD.

6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.95%), Ancora Advisors LLC (1.37%), BlackRock Inc. (1.38%) and Dimensional Fund Advisors LP (0.99%). Insiders that own company stock include Fred J Weinert, Michael I Schaffer, Peter Kamin and Raymond C Kubacki Jr.
View institutional ownership trends.

Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PMD stock can currently be purchased for approximately $4.81.

Psychemedics (NASDAQ:PMD) has a market capitalization of $27.52 million and generates $24.59 million in revenue each year. The company earns $-1,080,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

The company employs 139 workers across the globe.

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The official website for the company is www.psychemedics.com. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.